Advances in multidisciplinary therapy for meningiomas

International Consortium on Meningiomas, Priscilla K. Brastianos, Evanthia Galanis, Nicholas Butowski, Jason W. Chan, Ian F. Dunn, Roland Goldbrunner, Christel Herold-Mende, Franziska M. Ippen, Christian Mawrin, Michael W. McDermott, Andrew Sloan, James Snyder, Ghazaleh Tabatabai, Marcos Tatagiba, Joerg C. Tonn, Patrick Y. Wen, Kenneth Aldape, Farshad Nassiri, Gelareh Zadeh & 2 others Michael D. Jenkinson, David R. Raleigh

Research output: Contribution to journalArticle

Abstract

Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging meningiomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Radiation therapy has largely been used as a complementary and safe therapeutic strategy in meningiomas with evidence primarily stemming from retrospective, single-institution reports. Two of the first cooperative group studies (RTOG 0539 and EORTC 22042) evaluating the outcomes of adjuvant radiation therapy in higher-risk meningiomas have shown promising preliminary results. Historically, systemic therapy has resulted in disappointing results in meningiomas. However, several clinical trials are under way evaluating the efficacy of chemotherapies, such as trabectedin, and novel molecular agents targeting Smoothened, AKT1, and focal adhesion kinase in patients with recurrent meningiomas.

LanguageEnglish (US)
Pagesi18-i31
JournalNeuro-oncology
Volume21
Issue number1
DOIs
StatePublished - Jan 14 2019

Fingerprint

Meningioma
trabectedin
Therapeutics
Radiotherapy
Focal Adhesion Protein-Tyrosine Kinases
Clinical Trials
Recurrence
Drug Therapy
Wounds and Injuries

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Advances in multidisciplinary therapy for meningiomas. / International Consortium on Meningiomas.

In: Neuro-oncology, Vol. 21, No. 1, 14.01.2019, p. i18-i31.

Research output: Contribution to journalArticle

International Consortium on Meningiomas 2019, 'Advances in multidisciplinary therapy for meningiomas', Neuro-oncology, vol. 21, no. 1, pp. i18-i31. https://doi.org/10.1093/neuonc/noy136
International Consortium on Meningiomas. Advances in multidisciplinary therapy for meningiomas. Neuro-oncology. 2019 Jan 14;21(1):i18-i31. https://doi.org/10.1093/neuonc/noy136
International Consortium on Meningiomas. / Advances in multidisciplinary therapy for meningiomas. In: Neuro-oncology. 2019 ; Vol. 21, No. 1. pp. i18-i31.
@article{0a3ad02b94ca492f8ba9af89f8a45050,
title = "Advances in multidisciplinary therapy for meningiomas",
abstract = "Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging meningiomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Radiation therapy has largely been used as a complementary and safe therapeutic strategy in meningiomas with evidence primarily stemming from retrospective, single-institution reports. Two of the first cooperative group studies (RTOG 0539 and EORTC 22042) evaluating the outcomes of adjuvant radiation therapy in higher-risk meningiomas have shown promising preliminary results. Historically, systemic therapy has resulted in disappointing results in meningiomas. However, several clinical trials are under way evaluating the efficacy of chemotherapies, such as trabectedin, and novel molecular agents targeting Smoothened, AKT1, and focal adhesion kinase in patients with recurrent meningiomas.",
author = "{International Consortium on Meningiomas} and Brastianos, {Priscilla K.} and Evanthia Galanis and Nicholas Butowski and Chan, {Jason W.} and Dunn, {Ian F.} and Roland Goldbrunner and Christel Herold-Mende and Ippen, {Franziska M.} and Christian Mawrin and McDermott, {Michael W.} and Andrew Sloan and James Snyder and Ghazaleh Tabatabai and Marcos Tatagiba and Tonn, {Joerg C.} and Wen, {Patrick Y.} and Kenneth Aldape and Farshad Nassiri and Gelareh Zadeh and Jenkinson, {Michael D.} and Raleigh, {David R.}",
year = "2019",
month = "1",
day = "14",
doi = "10.1093/neuonc/noy136",
language = "English (US)",
volume = "21",
pages = "i18--i31",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Advances in multidisciplinary therapy for meningiomas

AU - International Consortium on Meningiomas

AU - Brastianos, Priscilla K.

AU - Galanis, Evanthia

AU - Butowski, Nicholas

AU - Chan, Jason W.

AU - Dunn, Ian F.

AU - Goldbrunner, Roland

AU - Herold-Mende, Christel

AU - Ippen, Franziska M.

AU - Mawrin, Christian

AU - McDermott, Michael W.

AU - Sloan, Andrew

AU - Snyder, James

AU - Tabatabai, Ghazaleh

AU - Tatagiba, Marcos

AU - Tonn, Joerg C.

AU - Wen, Patrick Y.

AU - Aldape, Kenneth

AU - Nassiri, Farshad

AU - Zadeh, Gelareh

AU - Jenkinson, Michael D.

AU - Raleigh, David R.

PY - 2019/1/14

Y1 - 2019/1/14

N2 - Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging meningiomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Radiation therapy has largely been used as a complementary and safe therapeutic strategy in meningiomas with evidence primarily stemming from retrospective, single-institution reports. Two of the first cooperative group studies (RTOG 0539 and EORTC 22042) evaluating the outcomes of adjuvant radiation therapy in higher-risk meningiomas have shown promising preliminary results. Historically, systemic therapy has resulted in disappointing results in meningiomas. However, several clinical trials are under way evaluating the efficacy of chemotherapies, such as trabectedin, and novel molecular agents targeting Smoothened, AKT1, and focal adhesion kinase in patients with recurrent meningiomas.

AB - Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging meningiomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Radiation therapy has largely been used as a complementary and safe therapeutic strategy in meningiomas with evidence primarily stemming from retrospective, single-institution reports. Two of the first cooperative group studies (RTOG 0539 and EORTC 22042) evaluating the outcomes of adjuvant radiation therapy in higher-risk meningiomas have shown promising preliminary results. Historically, systemic therapy has resulted in disappointing results in meningiomas. However, several clinical trials are under way evaluating the efficacy of chemotherapies, such as trabectedin, and novel molecular agents targeting Smoothened, AKT1, and focal adhesion kinase in patients with recurrent meningiomas.

UR - http://www.scopus.com/inward/record.url?scp=85060012470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060012470&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noy136

DO - 10.1093/neuonc/noy136

M3 - Article

VL - 21

SP - i18-i31

JO - Neuro-Oncology

T2 - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 1

ER -